STOCK TITAN

Tvardi gets FDA feedback on TTI-109 Phase 2 plans

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Tvardi Therapeutics, Inc. (TVRD) said it received written FDA responses to its pre-IND request for TTI-109, its oral STAT3 inhibitor being developed initially for ulcerative colitis. The FDA said the proposed nonclinical studies are appropriate to support a Phase 2 trial and provided guidance on dosing, study design, and patient selection. The feedback also addressed Crohn’s disease, which Tvardi is evaluating as a potential additional indication.

Tvardi plans to submit an IND in 2027; Phase 2 initiation remains subject to FDA review and clearance and the availability of additional funding. Tvardi says a new analysis comparing Phase 1 exposure in healthy volunteers with in-vitro activity levels supports the potential for sustained STAT3 inhibition at proposed doses, with minimal predicted effect on STAT1 and STAT5. TTI-109’s safety in patients with IBD has not been established.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Planned IND submission 2027 Tvardi plans to submit an IND for TTI-109 in 2027.
pre-IND regulatory
"pre-IND meeting request for TTI-109"
"Pre-ind" is short for "pre-indication" and refers to the period before a formal announcement or official signal that a significant change or event is about to happen, such as a company preparing to release important news. For investors, it can signal a time of increased activity or uncertainty, as market participants try to interpret hints and anticipate future developments. Recognizing pre-ind conditions helps investors make more informed decisions ahead of major shifts.
STAT3 inhibitor technical
"its oral STAT3 inhibitor"
A STAT3 inhibitor is a drug or molecule that blocks the activity of STAT3, a protein inside cells that helps switch on genes linked to cell growth, survival and inflammation. For investors, these inhibitors matter because they aim to slow or stop disease processes such as certain cancers and immune disorders; success or failure in development, safety and regulatory approval can strongly affect a company’s value, trial timelines and market opportunity.
prodrug medical
"TTI-109 is an orally administered prodrug of TTI-101"
A prodrug is an inactive or less-active compound that is designed to be converted into an active drug inside the body, like a packaged meal that needs heating before it's ready to eat. For investors, prodrugs matter because this design can improve how a medicine is absorbed, reduce side effects, extend patent protection, or enable new dosing forms — all factors that can affect a drug's regulatory path, marketability, and commercial value.
pharmacodynamic evidence medical
"providing pharmacodynamic evidence of STAT3 target engagement"
Janus kinase (JAK) inhibitors medical
"differs from that of Janus kinase (JAK) inhibitors"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the FDA say about TVRD’s TTI-109 development plan?

The FDA said the proposed nonclinical studies were appropriate to support a Phase 2 trial and provided guidance on dosing, study design, and patient selection. Its feedback addressed ulcerative colitis and Crohn’s disease; the company says the feedback is non-binding and may change after FDA reviews the full IND.

When could TVRD start Phase 2 testing of TTI-109?

Tvardi plans to submit an IND in 2027; Phase 2 initiation remains subject to FDA review and clearance and additional funding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001346830 0001346830 2026-11-19 2026-11-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) November 19, 2026

 

TVARDI THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36279   75-3175693
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)
         

3 Sugar Creek Ctr. Blvd.
Suite 525
Sugar Land, Texas

      77478
(Address of principal executive offices)       (Zip Code)

 

Registrant's telephone number, including area code: (713) 489-8654

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading
Symbol(s)
Name of each exchange on which
registered
Common Stock, par value $0.001 per share TVRD The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On November 19, 2026, Tvardi Therapeutics, Inc. (the "Company") issued a press release entitled "Tvardi Therapeutics Advances Next-Generation Oral STAT3 Inhibitor TTI-109 Toward IND in Inflammatory Bowel Disease Following FDA Pre-IND Feedback." The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press release issued on November 19, 2026.
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  TVARDI THERAPEUTICS, INC.
   
Date: November 19, 2026 By: /s/ Imran Alibhai
  Name: Imran Alibhai
  Title: Chief Executive Officer

 

 

 

Exhibit 99.1

 

 

Tvardi Therapeutics Advances Next-Generation Oral STAT3 Inhibitor TTI-109 Toward IND in Inflammatory Bowel Disease Following FDA Pre-IND Feedback

 

New analysis of Phase 1 exposure data supports the potential for sustained STAT3 inhibition at proposed clinical doses, with minimal predicted effect on STAT1 and STAT5

 

HOUSTON, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that it has received written responses from the U.S. Food and Drug Administration (FDA) to its pre-Investigational New Drug (pre-IND) meeting request for TTI-109, the Company’s next-generation oral STAT3 inhibitor. The meeting package outlined the Company’s plans for Phase 2 development of TTI-109 in inflammatory bowel disease (IBD).

 

Ulcerative colitis (UC) remains the Company’s initial indication for TTI-109. In addition, Tvardi is evaluating Crohn’s disease (CD), the other major form of IBD, as a potential additional indication. STAT3 is a key signaling protein in multiple pathways involved in both UC and CD, and the Company’s STAT3 inhibitors have demonstrated activity in preclinical models of both diseases. Given this biological overlap, Tvardi sought and received FDA feedback on both UC and CD, which gives the Company the flexibility to advance the two indications either in parallel or sequentially.

 

The FDA’s feedback was constructive and supports the Company’s development approach. The FDA agreed that the types of nonclinical studies summarized in the meeting package are appropriate to support a Phase 2 clinical trial, and provided guidance on dosing, study design and patient selection to inform the Company’s IND submission.

 

Tvardi plans to incorporate the FDA’s feedback and submit an IND in 2027. Initiation of the Phase 2 study remains subject to FDA review and clearance of the IND submission, as well as the availability of additional funding.

 

In addition to the regulatory update, Tvardi is reporting new data on TTI-109. The Company compared levels of TTI-101, the active form of TTI-109, measured in healthy volunteers in the Phase 1 study with the levels needed to block STAT1, STAT3 and STAT5 in human immune cells in cell culture. This analysis supports the potential for TTI-109 to provide sustained inhibition of STAT3 at the proposed clinical doses, with minimal predicted effect on STAT1 and STAT5.

 

This selectivity profile observed differs from that of Janus kinase (JAK) inhibitors, which inhibit signaling through multiple STAT pathways. The JAK inhibitors approved in IBD carry boxed warnings for serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis. Inhibition of STAT1 and STAT5 signaling, which helps the immune system fight viruses and supports natural killer (NK) cell and T-cell function, is believed to contribute to some of the safety risks reflected in these warnings. The Company believes that preferential inhibition of STAT3, with minimal predicted inhibition of STAT1 and STAT5, has the potential to support a differentiated safety profile, although the safety of TTI-109 in patients with IBD has not yet been established.

 

Page 1

 

 

“We are pleased with the FDA’s constructive feedback, which is in line with our expectations, supports our overall approach to developing TTI-109 and gives us clear direction as we prepare our IND submission,” said John Kauh, M.D., Chief Medical Officer of Tvardi. “STAT3 is a central driver of immune dysregulation, inflammation and fibrosis that underlie inflammatory bowel disease. Building on our positive Phase 1 results, including a new analysis supporting the potential for sustained STAT3 inhibition with minimal STAT1 and STAT5 inhibition at the proposed clinical doses, we believe TTI-109 may offer a differentiated oral treatment option for patients with inflammatory bowel disease. We look forward to advancing TTI-109 into Phase 2 development, subject to IND clearance and the availability of additional funding.”

 

About TTI-109

 

TTI-109 is an orally administered prodrug of TTI-101, a small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3). In a Phase 1 healthy volunteer study, TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and demonstrated reductions in cellular and humoral immune populations known to correlate with UC disease severity, providing pharmacodynamic evidence of STAT3 target engagement.

 

About Inflammatory Bowel Disease

 

Ulcerative colitis and Crohn’s disease are the two main forms of inflammatory bowel disease (IBD), chronic immune-mediated conditions that cause inflammation of the gastrointestinal tract. Despite the availability of biologic and small molecule advanced therapies, many patients do not respond adequately or lose response over time, leaving a significant need for new treatment options with novel mechanisms of action.

 

About Tvardi Therapeutics

 

Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive immune dysregulation, inflammation and proliferation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The Company has completed a Phase 1 healthy volunteer study of TTI-109 and plans to initiate clinical trials of TTI-109 in ulcerative colitis pending IND clearance and the availability of additional funding. The Company is also conducting a Phase 1b/2 clinical trial of TTI-101 in hepatocellular carcinoma (NCT05440708). To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).

 

Cautionary Statement Regarding Forward-looking Statements

 

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the FDA’s pre-IND feedback; the anticipated timing and content of the Company’s submission of the IND for TTI-109 and the FDA’s review thereof; the planned design and conduct of clinical trials of TTI-109 and its potential development in UC and CD; the predicted STAT pathway selectivity of TTI-109 and its potential to offer a differentiated safety profile relative to JAK inhibitors; the anticipated benefits of Tvardi’s product candidates; its ongoing clinical trials and anticipated timing of reporting data from such trials; potential indications for its product candidates; its anticipated cash runway and the availability of additional funding to advance Tvardi’s clinical development of TTI-109 in UC and/or CD; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them.

 

Page 2

 

 

Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are subject to a number of risks, including, among other things: the uncertainties associated with Tvardi’s product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the completion of clinical trials or safety or other complications related to its product candidates; the ability to obtain IND clearance for TTI-109 in UC and/or CD on the timelines expected or at all; the fact that pre-IND feedback from the FDA is non-binding and may change upon the FDA’s review of the full IND submission; the possibility that the FDA may raise additional comments, request additional data or not agree with the proposed doses or study design upon review of the IND submission; the ability to replicate results for preclinical studies and early clinical trials in later trials; the risk that the predicted STAT3 selectivity of TTI-109, which is based on modeling of exposures in healthy volunteers relative to in vitro data, may not be observed in patients or may not result in a differentiated safety profile or other clinical benefit; the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all; the significant net losses Tvardi has incurred since inception; Tvardi’s ability to initiate and complete ongoing and planned preclinical studies and clinical trials and advance its product candidates through clinical development; the timing of the availability of data from Tvardi’s clinical trials; the outcome of preclinical testing and clinical trials of Tvardi’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; Tvardi’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Tvardi’s product candidates; Tvardi’s anticipated cash runway; Tvardi’s ability to attract, hire, and retain skilled executive officers and employees; Tvardi’s ability to protect its intellectual property and proprietary technologies; Tvardi’s reliance on third parties, contract manufacturers, and contract research organizations; the possibility that Tvardi may be adversely affected by other economic, business, or competitive factors; risks associated with changes in applicable laws or regulations; those factors discussed in Tvardi’s filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Annual Report on Form 10-K for the year ended December 31, 2025, and Tvardi’s other documents subsequently filed with or furnished to the SEC, all of which are available on the SEC’s website at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

 

Contacts:

 

For Tvardi:

Tvardi Investor Relations

ir@tvardi.com

 

PJ Kelleher

LifeSci Advisors

617-430-7579

pkelleher@lifesciadvisors.com

 

# # #

 

Page 3

 

Filing Exhibits & Attachments

4 documents

Keep reading